What is the appropriate management for a female patient with ongoing heavy menstrual bleeding and a hemoglobin of 7.2 g/dL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Heavy Menstrual Bleeding with Hemoglobin 7.2 g/dL

This patient requires immediate multidisciplinary intervention with supportive care (blood transfusion and/or IV iron), acute bleeding control with high-dose hormonal therapy or tranexamic acid, and iron supplementation—whether or not she receives transfusion—followed by definitive long-term menstrual management. 1, 2

Immediate Assessment and Stabilization

Check hemodynamic status immediately: Measure orthostatic blood pressure and pulse to assess volume depletion 3. With hemoglobin at 7.2 g/dL, this patient has severe anemia requiring urgent intervention.

Supportive care options include:

  • Blood transfusion if hemodynamically unstable, actively bleeding heavily, or symptomatic (fatigue, dyspnea, tachycardia) 1
  • IV iron infusion (iron dextran, ferric carboxymaltose, or iron sucrose) as an alternative or adjunct, particularly if transfusion is declined or bleeding is controlled 1, 4
  • Recent evidence shows hemoglobin recovery occurs substantially even without transfusion when bleeding is controlled, though transfusion may be necessary in selected cases 5

The critical point: Iron supplementation is mandatory regardless of whether transfusion is given, as iron stores (ferritin) recover much more slowly than hemoglobin 2, 5.

Acute Bleeding Control

First-line medical management includes:

Tranexamic acid (antifibrinolytic):

  • Oral: 1300 mg three times daily during bleeding
  • IV: 10 mg/kg every 8 hours if unable to take oral
  • Can be used immediately and is highly effective for acute control 1, 2, 3

High-dose hormonal therapy (if not contraindicated):

  • Combined hormonal contraceptives: 1 pill every 8 hours until bleeding stops (typically 24-48 hours), then taper
  • OR high-dose progestins: norethindrone 5-10 mg three times daily 3, 6

If medical management fails or bleeding is life-threatening:

  • Intrauterine Foley catheter balloon tamponade for severe hemorrhage 1, 7
  • Dilation and curettage with immediate LNG-IUS placement 7
  • Endometrial ablation in select cases 7

Bridging Phase (Often Overlooked)

After acute bleeding stops, a bridging phase is critical to prevent recurrence while anemia improves 6. This vulnerable period requires:

  • Continuous progestin therapy (norethindrone 5 mg daily) OR
  • Continuous combined hormonal contraceptives (skip placebo pills) OR
  • Depot medroxyprogesterone acetate injection for reliable amenorrhea 6
  • Continue tranexamic acid during any breakthrough bleeding 6

This phase typically lasts 2-3 months until hemoglobin normalizes and definitive therapy can be safely implemented 6.

Iron Repletion (Mandatory)

Iron supplementation is required whether or not anemia is present 2:

Oral iron:

  • Ferrous sulfate 325 mg (65 mg elemental iron) every other day on empty stomach (better absorbed and tolerated than daily dosing) 4
  • Continue until ferritin >30 ng/mL, not just until hemoglobin normalizes 4

IV iron preferred if:

  • Oral iron not tolerated or ineffective after 4-6 weeks
  • Ongoing heavy bleeding despite treatment
  • Need for rapid repletion 4, 8
  • Single-dose IV iron formulations improve adherence and quality of life 8

Critical caveat: Ferritin recovery lags significantly behind hemoglobin improvement—patients may have normal hemoglobin but remain iron deficient for months 5. Check ferritin at follow-up, not just hemoglobin.

Long-Term Maintenance

Levonorgestrel-releasing IUD (LNG-IUS) is the most effective long-term option:

  • Reduces menstrual blood loss by 71-95% at 6 months 9, 7
  • Increases hemoglobin significantly (mean increase ~37 g/L) 7
  • Dramatically improves quality of life 7
  • Should be placed after bleeding is controlled and hemoglobin improves, not during acute bleeding 6

Alternative long-term options:

  • Combined hormonal contraceptives (continuous or cyclic)
  • Depot medroxyprogesterone acetate injections
  • Oral progestins (norethindrone)
  • Tranexamic acid during menses only 9

Evaluation for Underlying Bleeding Disorder

Screen for bleeding disorders in all adolescents and women with heavy menstrual bleeding requiring this level of intervention 3:

  • Complete blood count with platelet count
  • PT/aPTT
  • Von Willebrand factor antigen and activity
  • Factor VIII level
  • Consider platelet function testing if above normal 3

Coordinate with hematology if bleeding disorder suspected or confirmed 1.

Follow-Up Strategy

Reassess at 4-6 weeks:

  • Hemoglobin and ferritin levels (not just hemoglobin)
  • Menstrual bleeding pattern (use PBAC score if available)
  • Medication adherence and side effects
  • Transition from bridging to definitive therapy if stable 6

Continue monitoring every 3 months until:

  • Hemoglobin >12 g/dL
  • Ferritin >30 ng/mL
  • Menstrual bleeding controlled on maintenance therapy 4, 6

Common Pitfalls to Avoid

  • Don't stop at hemoglobin normalization—iron stores must be repleted or anemia will recur 2, 5
  • Don't place LNG-IUS during active heavy bleeding—control bleeding first, then place during bridging phase 6
  • Don't forget the bridging phase—jumping directly from acute control to long-term maintenance risks recurrent bleeding 6
  • Don't assume all hormonal therapy is contraindicated—even in patients with prior thrombosis, progestin-only options and local therapy (LNG-IUS) are generally safe 1
  • Don't use oral iron daily—alternate-day dosing improves absorption and tolerability 4

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.